Nome Químico: N-((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)-N-(3-((1R,2S,3S,4S)-2,3-dihydroxy-4-(2-hydroxyethoxy)cyclopentyl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)nitrous amide hydrochloride
Sorrisos: CCCSC1=NC(N([C@H]2[C@H](C3=CC=C(F)C(F)=C3)C2)N=O)=C4C(N([C@@H]5C[C@H](OCCO)[C@@H](O)[C@H]5O)N=N4)=N1.Cl
Inchi: InChI=1S/C4H2ClFN2/c5-4-3(6)1-7-2-8-4/h1-2H
Estimation Of Ticagrelor In Commercial Dosage Form Using A Sensitive Validated RP-HPLC Method
By Madhuri, K.; Rao, Y. Srinivasa; Varaprasada, Rao K.; Deepthi, R.
From World Journal of Pharmaceutical Research (2021), 10(6), 1281-1292.
Development and validation of stability indicating RP-HPLC method for the estimation of Ticagrelor by forced degradation studies
By Dole, Manjusha; Kendre, Meenakshi; Wagh, Viplav
From World Journal of Pharmacy and Pharmaceutical Sciences (2019), 8(5), 711-724
Development of a validated HPLC-PDA method for stability indicating study of ticagrelor: a novel anti-platelet agent (P2Y12-ADP receptor blocker)
By Sulthana, Shabana; Anuradha, V.; Rao, Mandava V. Basaveswara
From International Journal of Pharmaceutical, Chemical and Biological Sciences (2017), 7(1), 36-42